In 2002, Bill co-founded Alba BioPharm Advisors, and as president and medical consultant he currently
provides a wide variety of consulting services for the company's small, mid-sized and large pharma clients.
Bill has acted as medical advisor for Gloucester Pharmaceuticals from
2003 to the present, and served as Executive Vice President and Chief Medical Officer from 2004-2007.
During this period he provided the medical expertise which was instrumental in the acquisition, clinical development
and ultimate FDA approval of the company's anticancer agent, romidepsin (Istodax). Since Gloucester's acquisition by Celgene Corporation
in December 2009, he has continued to provide services to the company as a senior medical advisor.
co-founding Alba BioPharm Advisors, Bill served as Executive Vice President & Medical Director of A.M. Pappas &
Associates, LLC, a North Carolina life sciences venture development firm. From 1997 until 2002 he developed and managed the
company’s international pharmaceutical and biotechnology advisory practice, with clients ranging from large pharmaceutical
firms to start-up companies. In addition, he provided due diligence and other services in support of the company’s significant
venture capital activities.
Previous U.S. appointments have included Senior Vice President of R&D for Sparta Pharmaceuticals (1992–97), and
Vice President of Clinical R&D for U.S. Bioscience (1988-92). While residing in Europe, he held senior executive positions
with Bristol-Myers Co., Celltech Ltd., and Astra Alab, a division of Astra AB (now Astra Zeneca).
Bill earned his
M.B., Ch.B. (M.D. equivalent) from the University of Glasgow in Scotland, is a Member of the Royal College of Physicians (UK), Fellow
of the Royal College of Physicians (Glasgow) and Fellow of the Faculty of Pharmaceutical Medicine, UK. In addition, he
holds a Diploma from the Royal College of Obstetricians and Gynaecologists, UK. He is a member of the American Society
of Clinical Oncology.